
Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. This meta-analysis aimed to assess the efficacy of abiraterone, enzalutamide and docetaxel in BRCA1/2 mutation-positive mCRPC patients in terms of PSA-response (PSA50), progression-free survival (PFS) and overall survival (OS). The PSA50 analyses revealed that all three first-line treatments have a therapeutic effect in BRCA1/2 positive mCRPC. However, based on PSA50 and PFS analyses, BRCA-positive mCRPC patients might better respond to enzalutamide treatment. However, molecular marker-driven interventional studies directly comparing these agents are crucial for providing higher-level evidence.
Like
Save
Share